Posted by Michael Wonder on 02 Jul 2020
Johnson & Johnson announces European Commission approval for Janssen’s preventive Ebola vaccine
1 July 2020 - This marks the first major regulatory approval of a vaccine developed by Janssen.
Johnson & Johnson today announced that the European Commission has granted marketing authorisation for its Janssen Pharmaceutical Companies’ Ebola vaccine regimen for the prevention of Ebola virus disease.
Enabled by this approval, Janssen is now collaborating with the World Health Organization on vaccine pre-qualification, which should help accelerate registration of its preventive Ebola vaccine regimen in African countries and facilitate broader access to those most in need.
